CA Patent

CA3051420A1 — Crac channel inhibitor compositions

Assigned to Calcimedica Inc · Expires 2018-08-02 · 8y expired

What this patent protects

Provided herein are pharmaceutical compositions, such as emulsions and nanosuspensions, comprising a CRAC channel inhibitor. Also provided herein are methods of treating pancreatitis, viral infections, stroke, traumatic brain injury, fibrosis, inflammation, and autoimmune disease…

USPTO Abstract

Provided herein are pharmaceutical compositions, such as emulsions and nanosuspensions, comprising a CRAC channel inhibitor. Also provided herein are methods of treating pancreatitis, viral infections, stroke, traumatic brain injury, fibrosis, inflammation, and autoimmune diseases by administering such pharmaceutical compositions.

Drugs covered by this patent

Patent Metadata

Patent number
CA3051420A1
Jurisdiction
CA
Classification
—
Expires
2018-08-02
Drug substance claim
No
Drug product claim
No
Assignee
Calcimedica Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.